Arcturus TherapeuticsvsThermo Fisher Scientific

ARCT and TMO stock compared: price, dividend, valuation and results, from SEC filings.

ARCT

Arcturus Therapeutics Holdings Inc.

$8.36

Value $238M

-0.95%
ARCT's page

TMO

Thermo Fisher Scientific Inc

$700.22

Value $260B

+0.11%
TMO's page

Arcturus Therapeutics (ARCT) has a market value of $238M and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, ARCT moved +2.8% and TMO +19.5%. Dividend yield: ARCT none, TMO 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ARCT$238M

    TMO$260B

    TMO is 1,095 times ARCT

  • Revenue, 12 months

    ARCT$31M

    TMO$47.4B

    TMO is 1,552 times ARCT

  • Net income, 12 months

    ARCT-$87M

    TMO$7.1B

  • Operating margin

    ARCT-311.2%

    TMO17.9%

    329.1 points apart

  • ROIC

    ARCT-38.7%

    TMO8.2%

    46.8 points apart

  • P/E

    ARCT–

    TMO36.8

  • Dividend yield

    ARCT0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    ARCT-77.8%

    TMO+11.8%

    89.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ARCT-77.8%

TMO+11.8%

5010020222023202420252026
Returns by period
PeriodARCTWith dividendsTMOWith dividends
1 year since November 12, 2025+2.8%Price +2.8%+19.5%Price +19.1%
3 years since November 13, 2023-52.8%-22.1% a yearPrice -52.8%+58.8%+16.7% a yearPrice +57.3%
5 years since November 12, 2021-77.8%-26.0% a yearPrice -77.8%+11.8%+2.3% a yearPrice +10.2%
10 years since November 15, 2016-35.4%-4.3% a yearPrice -35.4%+384.5%+17.1% a yearPrice +371.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ARCTArcturus TherapeuticsTMOThermo Fisher Scientific

Valuation

ARCTTMO
Valuation
Price$8.36$700.22
Market value$238M$260B
Enterprise value (EV)$53M$295B
P/E–36.8
P/E, 5-year median–32.7
P/B1.44.8
EV/EBIT–34.9
Free cash flow yield–2.9%

Results and growth

ARCTTMO
Results and growth
Revenue, 12 months$31M$47.4B
Net income, 12 months-$87M$7.1B
Free cash flow, 12 months-$63M$7.6B
Earnings per share, 12 months-$3.10$18.96
Revenue growth, year on year-46.1%3.9%
Revenue growth a year, past+53.8%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

ARCTTMO
Margins and returns on capital
Gross margin––
Operating margin-311.2%17.9%
Net margin-285.9%14.9%
ROIC-38.7%8.2%
ROE-45.0%13.4%

Balance sheet

ARCTTMO
Balance sheet
Cash$185M$6.1B
Total debt$22M$41.4B
Net debt / EBITDA–3.7
Interest cover–5.5×

Dividends and buybacks

ARCTTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ARCT or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Arcturus Therapeutics or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($260B) is about 1,094.7 times Arcturus Therapeutics ($238M), at today's prices.

How did ARCT and TMO stock do over the last 10 years?

Since November 15, 2016, ARCT's price moved -35.4% and TMO's +371.0%. With dividends: ARCT -35.4% (-4.3% a year), TMO +384.5% (+17.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ARCT or TMO?

The dividend yield at today's price is none for Arcturus Therapeutics and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Arcturus Therapeutics or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -285.9% for Arcturus Therapeutics and 14.9% for Thermo Fisher Scientific, and the operating margin -311.2% and 17.9%. Revenue was $31M and $47.4B.

Which is the better investment, Arcturus Therapeutics or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.